Evidence map›Paper›PMID 34113728›Full record

ArticleHeliyon2021

Reversible splenial lesion syndrome in sisters with sensorineural deafness as the first manifestation.

Jinbo Yang, Xiaodan Ma, Rujuan Li, Xiaohui Ma, Junmin Chen, Xiangjian Zhang

Open access · goldAbstract readCase Reports
In one paragraph

Article in Heliyon, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Bilateral hearing loss as the initial presentation of reversible Wernicke's encephalopathy with splenial lesion.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jinbo YangDepartment of Neurology, Ninth Hospital of Xingtai City, Xingtai, Hebei, 055250, China.
Xiaodan MaDepartment of Neurology, Ninth Hospital of Xingtai City, Xingtai, Hebei, 055250, China.
Rujuan LiDepartment of Neurology, Ninth Hospital of Xingtai City, Xingtai, Hebei, 055250, China.
Xiaohui MaDepartment of Neurology, Ninth Hospital of Xingtai City, Xingtai, Hebei, 055250, China.
Junmin ChenDepartment of Neurology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, China.
Xiangjian ZhangDepartment of Neurology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, China.
Hebei Medical University · CNSecond Hospital of Hebei Medical University · CNXingtai People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reversible splenial lesion syndrome (RESLES) is a rare clinico-radiological disorder syndrome with unclear pathophysiology. Here, two sisters with sensorineural deafness as the chief complaint diagnosed with RESLES was reported. Although the sisters had the disease successively, they were divided into two types on imaging by isolated lesions of splenium of the corpus callosum (SCC) and extensive lesions of the corpus callosum. The clinical manifestations and lesions on MRI disappeared after 6 months. The sensorineural deafness of the sisters in this article may be caused by transcallosal auditory pathway (TCAP) injury. Auditory handicap has been found in previous RESLES cases, indicating that we know little about the connection between the SCC and the auditory pathway, and further research is needed.

Indexed as

Corpus callosumReversible splenial lesion syndromeSensorineural deafness

Identifiers

PMID34113728
PMCPMC8170165
OpenAlexW3165172440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.